Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A

Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A

SSSE:603139
26.36
CNY
-0.81
(-2.98%)
-1.81EPS
3.64BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.53
5.03
5.07
5.09
4.02
3.78
4.34
4.13
4.49
4.91
6.69
5.64
4.72
5.13
Basic EPS, GAAP
0.77
0.84
0.83
0.87
0.69
0.56
0.43
0.34
0.37
-0.63
-0.26
-0.9
-3.34
-1.97
Free Cash Flow per Basic Share
-0.16
0.05
0.21
0.89
0.44
0.57
0.26
-1.69
-2.87
-0.88
-1.44
-0.09
-0.32
- -
Dividend per Share
0.04
0.03
0.03
0.02
0.05
0.21
0.12
0.1
0.34
0.32
0.31
0.29
0.28
0.23
Book Value per Share
4.44
5.28
6.11
6.98
9.12
9.47
9.79
10.09
10.48
9.75
9.5
8.58
5.26
6.32
Tangible Book Value per Share
3.96
4.81
5.23
6.13
8.21
8.59
8.94
8.55
8.97
8.46
8.32
7.4
4.32
5.45
Basic Weighted Avg Shares
72
75
75
75
91
99
99
100
99
100
101
100
100
101
Sales/Revenue/Turnover
328
376
380
382
367
376
431
414
443
492
673
562
471
520
Operating Margin (%)
21.4
21
21.03
20.19
18.9
14.7
11.2
10.49
6.18
2.31
1.44
-6.53
-17.99
-7.83
Depreciation Expense
7
9
9
9
10
11
12
12
16
25
38
60
66
- -
Net Income, GAAP
56
63
62
65
63
56
43
34
36
-63
-26
-90
-333
-200
Effective Tax Rate (%)
15.22
15.18
15.21
15.17
13.85
15.42
17.54
16.28
14.49
- -
- -
- -
- -
- -
Profit Margin (%)
17.02
16.7
16.38
17.08
17.17
14.81
9.91
8.24
8.24
-12.83
-3.89
-15.96
-70.75
-38.36
Working Capital
207
261
320
388
774
790
714
356
348
219
1
1
-341
-820
LT Debt
7
- -
- -
- -
2
7
- -
28
393
386
284
334
246
332
Total Equity
333
395
458
523
912
979
1,017
1,073
1,115
1,026
1,020
907
569
753
Return on Invested Capital (%)
17.06
15.06
13.2
11.86
8.44
5.69
4.59
3.35
2.44
- -
- -
- -
- -
- -
Return on Capital (%)
18.67
16.21
13.87
12.83
8.68
5.64
3.9
3.03
3.31
- -
- -
- -
- -
- -
Return on Common Equity (%)
20.56
17.24
14.59
13.31
8.79
5.99
4.44
3.44
3.55
-6.24
-2.72
-9.92
-48.25
-26.79

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
389
393
537
LT Borrowings
177
122
152
LT Finance Leases
- -
31
180
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
100
100
106
Market Capitalization
2,639
4,206
3,639

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
555
695
754
Cash, Cash Equivalents & STI
53
62
127
Accounts Receivable, Net
202
172
196
Inventories
190
308
225
Total Current Liabilities
884
1,178
1,574
Payables & Accruals
- -
- -
- -
ST Debt
389
393
537
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.24%
-10.6%
-37.26%
Free Cash Flow
-26.6%
42.77%
244.36%
Net Income, GAAP
13.66%
38.05%
272.05%
Sales/Revenue/Turnover
3.21%
4.45%
-16.09%
Total Cash Common Dividend
67.56%
43.38%
-3.71%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
127
138
139
157
562
2025
121
126
- -
115
471
2026
93
112
200
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
-0.1
-0.3
-0.51
-0.9
2025
-0.17
-0.23
- -
-2.01
-3.34
2026
0.21
-0.12
-0.07
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.06
0.07
0.09
0.29
2025
0.06
0.07
- -
0.07
0.28
2026
0.05
0.06
0.05
- -
- -

Company Description

CEO
Jing Wang
Full Time Employees
804
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 36 Yanzhi Road Xianyang SA China 712000
IPO Date
Apr 21, 2017
Website
sxkh.com
Business
Shaanxi Kanghui Pharmaceutical Co., Ltd. Shaanxi Kanghui Pharmaceutical Co., Ltd. (603139.SS) engages in the research, development, production, and sale of pharmaceutical products primarily in China. Founded in 1999 and headquartered in Xianyang, Shaanxi Province, the company manufactures a diverse portfolio of proprietary Chinese medicines and other drugs targeting gynecological, orthopedic, dermatological, diabetes, respiratory system, urinary system, cardiovascular and cerebrovascular, gastrointestinal, hepatobiliary, and tranquilizer conditions; these are offered in forms including tablets such as Compound Double Flower Tablets, capsules like Kunfukang Capsules and Cinnamon Bone Pain Capsules, granules including Silver Eliminating Granules and Astragalus Medicine Thirst Quenching Granules, mixtures, teas, plasters, ointments, liniments, lotions, and tinctures. It also conducts pharmaceutical distribution encompassing wholesale of biologics, blood products, pharmaceuticals, and Chinese herbal medicines, alongside involvement in Chinese medicine tablets and chemical intermediates. The company, which completed shareholding system reform in 2009 and listed on the Shanghai Stock Exchange main board in April 2017, operates as a national high-tech enterprise with wholly-owned and holding subsidiaries in drug distribution, medical devices, and private equity funds. Recent developments include the agreement to acquire a 51% stake in Shaanxi Xingaoxin Pharmaceutical Co., Ltd., enhancing its product portfolio and strategic positioning in the competitive Chinese pharmaceutical market.